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Abstract
Background:  Glioma present as one of the most challenging cancers to treat, however,
understanding of tumor cell biology is not well understood. Extracellular adenosine triphosphate
(ATP) could serve as a critical signaling molecule regulating tumor development. This study has
examined pharmacological modulation of calcium (Ca2+) entry through store-operated channels
(SOC) on cellular expression and production of immune-cell mobilizing chemokines in ATP-
stimulated C6 glioma cells.
Methods: Calcium spectrofluorometry was carried out to measure mobilization of intracellular
Ca2+ [Ca2+]i following ATP stimulation of rat C6 glioma cells. Pretreatment with two inhibitors of
SOC, SKF96365 or gadolinium, was used to examine for effects on [Ca2+]i. RT-PCR was performed
to determine effects of purinergic stimulation on C6 cell expression of metabotropic P2Y receptors
(P2YR) and the chemokines, monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-
8). ELISA was carried out to measure production of MCP-1 and IL-8 with ATP stimulation of glioma
cells.
Results: Application of ATP (at 100 μM) to C6 glioma induced an increase in [Ca2+]i with the
response exhibiting two components of decay. In the presence of the SOC inhibitors, SKF96365
or gadolinium, or with Ca2+-free solution, ATP responses lacked a slow phase suggesting the
secondary component was due to SOC-mediated influx of Ca2+. RT-PCR confirmed expression of
purinergic P2Y-subtype receptors in C6 cells which would serve as a precursor to activation of
SOC. In addition, ATP-stimulated C6 cells showed enhanced expression of the chemokines, MCP-
1 and IL-8, with SKF96365 or gadolinium effective in reducing chemokine expression. Gadolinium
treatment of ATP-stimulated C6 cells was also found to inhibit the production of MCP-1 and IL-8.
Conclusion: These results suggest ATP-induced Ca2+ entry, mediated by activation of SOC in C6
glioma, as a mechanism leading to increased cellular expression and release of chemokines. Elevated
levels of MCP-1 and IL-8 are predicted to enhance the mobility of tumor cells and promote
recruitment of microglia into developing tumors thereby supporting tumor growth.
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Background
Gliomas are a common form of human brain tumor but
remain essentially incurable due to their innate character-
istic of extreme invasiveness [1]. The development and
progression of gliomas include reciprocal interactions
between glioma cells with resident immune responding
microglia and tumor-associated macrophages [2,3]. In
particular, evidence suggests that tumor cells may produce
mobilizing factors for microglia/macrophages and that
chemokine responses of microglia could aid in establish-
ing immunosuppressive environments facilitating tumor
growth [4,5]. Among the most prominent glioma chem-
okine factors are monocyte chemoattractant protein-1
(MCP-1) and interleukin-8 (IL-8) which could induce
recruitment of microglia/macrophage to help support
tumor progression [6,7]. Moreover, MCP-1 has been
shown to directly induce angiogenesis [8] while both
chemokines also act as autocrine factors to drive the inva-
sive phenotypes of the gliomas [6,9].
A spectrum of stimulatory signals is likely present in
developing gliomas which activate microglial chemotactic
responses and promote an overall immunosuppressive
microenvironment. In particular, purinergic signaling
pathways in glioma may be highly relevant in enhance-
ment of chemotactic factors to recruit microglia to help
sustain tumor growth [10,11]. Glioma cells both release
and respond to ATP [12,13] with catabolism of ATP
extremely low in glioma cells, compared to astrocytes, due
to a marked reduction in expression and activity of
enzymes that degrade ATP [14]. Importantly, depletion of
ATP has been reported to reduce the size and invasive
characteristics of tumors in an animal glioma model [15].
Evidence suggests that mobilization of intracellular cal-
cium ([Ca2+]i), mediated by activation of the purinergic
subtype receptor, P2X7R by the ligand 2',3'-(benzoyl-4-
benzoyl)-ATP (BzATP), serves as a link between ATP stim-
ulation of glioma and cellular expression of chemokine
and cytokine factors [16]. However, roles of other purin-
ergic family members were also suggested since antago-
nism of P2X7R had no effect to inhibit factor expression
and only partially suppressed calcium responses [16]. In
particular, it was speculated that subtype P2YR could also
be activated by BzATP thereby increasing [Ca2+]i by a
rapid release from endoplasmic stores followed by a sub-
sequent sustained influx of the ion through store-oper-
ated channels (SOC). These findings suggested the
relevance of study using the endogenous compound ATP
as an activator of C6 cells to determine effects of pharma-
cological modulation of SOC-mediated Ca2+ entry on cel-
lular production of chemokines.
Methods
Materials
All chemicals were purchased from Sigma (St.Louise, MO)
unless otherwise stated. Two inhibitors of SOC were
employed in this work; gadolinium [17,18] and
SKF96365 [19].
Cell culture
C6 glioma cells were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). Cells from pas-
sage number 39-59 were used in this work. Cells were cul-
tured in Kaighn's modification of Ham's F12 medium
(F12K) with 2 mM l-glutamine modified by ATCC to con-
tain 1.5 g/l sodium bicarbonate. The medium was then
supplemented with 15% horse serum, 2.5% fetal bovine
serum, 0.5 μg/ml fungizone (Invitrogen: GIBCO, Grand
Island, NY) and 0.02 mg/ml gentamicin (Invitrogen:
GIBCO). Cells were maintained in 100 mm culture dishes
(SARSTEDT, Newton, NC) at 37°C in a humidified 5%
CO2 air atmosphere.
Calcium spectrofluorometry
The detailed procedure for calcium imaging was carried
out as published [20]. Briefly, cultured C6 glioma cells
were incubated with fura-2 acetoxymethyl ester (fura-
2AM at 1 μM; Molecular Probes, Eugene, OR) and
pluronic acid (at 1 μM) in normal physiological saline
solution (PSS) for 20 min at room temperature (20-
22°C). Cells were then washed with PSS solution contain-
ing (in mM): 126 NaCl, 5 KCl, 1 CaCl2, 1.2 MgCl2, 10
HEPES and 10 glucose (pH 7.4). In some experiments,
Ca2+-free PSS was used; this solution had the same com-
position as PSS with the exception that EGTA was added
(at 1 mM) with no CaCl2. Coverslips were placed in a per-
fusion chamber mounted on an inverted microscope
(Zeiss, Jena, Germany) and fluorescence was measured
through a 40× quartz objective lens. Alternating wave-
lengths (340/380 nm) of ultraviolet light were applied at
6-s intervals for excitation and fluorescence signals were
measured at 510 nm of emission light. Signals were
acquired from a digital camera (DVC-1310, DVC Co. Aus-
tin, TX) and were processed using an imaging system
(Empix, Mississauga, ON, Canada) to determine ratios of
the 340 and 380 nm intensities which were used as quan-
titative measures of fluorescence levels in this work.
Semiquantitative RT-PCR
C6 glioma cells (8 × 105 cells/well) were plated in serum-
free media and the experiment was carried out the follow-
ing day with addition of ATP (100 μM) in the absence or
presence of SKF96365 (25 μM) or gadolinium (1 μM) for
4 h. Total RNA was isolated using TRIzol (Invitrogen:
GIBCO) and then processed for the first strand comple-
mentary DNA (cDNA) synthesis using Moloney murine
leukemia virus (M-MLV) reverse transcriptase (Invitrogen:BMC Cancer 2009, 9:442 http://www.biomedcentral.com/1471-2407/9/442
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GIBCO). The cDNA products were then amplified by PCR
using a GeneAmp thermal cycler (Applied Biosystems,
Foster City, CA). Specific sense and antisense primers with
the expected product sizes are shown in Table 1. PCR con-
ditions were as follows: initial denaturation at 95°C for 6
min followed by a 25- to 35- cycle amplification program
consisting of denaturation at 95°C for 45 s, annealing at
55-60°C for 1 min and extention at 72°C for 1 min. A
final extention was carried out at 72°C for 10 min. For
P2YR expression study, the PCR cycle was set at 35 cycles
for all subtype receptors. Amplification of the constitu-
tively expressed enzyme D-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a reaction standard.
The amplified PCR products were identified using 1.5%
agarose gels containing ethidium bromide (final concen-
tration 0.5 μg/ml) and visualized under ultraviolet light.
The intensities of each band were measured by densitom-
etry using NIH Image J 1.37b software (National Institute
of Health, Bethesda, MD) and expressed as relative mRNA
levels (mRNA levels normalized to GAPDH).
ELISA
C6 cells were plated using serum-free media in a 24-well
plate at 3 × 105 cells/well and were allowed to acclimate
for 24 h before starting the experiment. ATP was applied
to the cells with or without gadolinium for 48 h and cul-
ture media were collected and analyzed with rat MCP-1
and rat IL-8 (GRO/KC) ELISA kit (Peprotech, Rockey Hill,
NJ) according to the manufacturer's protocol. The detec-
tion limits were 47 and 16 pg/ml for MCP-1 and IL-8,
respectively.
Statistical analysis
Data are presented as means ± standard error of mean
(SEM). Statistical significance (p < 0.05) was evaluated
using one-way analysis of variance followed by Student-
Newman-Keuls multiple comparison test (GraphPad
Prism 3.0; San Diego, CA).
Results
ATP-induced changes in Ca2+ mobilization
Application of ATP (100 μM) to C6 glioma cells resulted
in an early phase of increased [Ca2+]i which rapidly
declined and was followed by a sustained component of
response (Fig. 1A). In the presence of Ca2+-free PSS (0
PSS), ATP administration led to a single phase of [Ca2+]i
mobilization representing only the rapid portion of the
response (Fig. 1B). These results suggested ATP binding to
a P2YR activating an inositol 1,4,5-trisphosphate (IP3)-
mediated intracellular release of Ca2+ and a subsequent
entry of divalent ion through SOC [21,22]. To test this
possibility two inhibitors of SOC, gadolinium and
SKF96365, were applied prior to ATP stimulation. The
concentrations of gadolinium (at 1 μM) [18] and
SKF96365 (at 25 μM) [23,24] were chosen according to
ones used in previous studies which were found effective
for SOC inhibition. Representative ATP responses are pre-
sented with pre-treatment (3 min) with gadolinium (Fig.
1C) or SKF96365 (Fig. 1D). Exposure of C6 to either SOC
inhibitor yielded a pattern of ATP response close to that
observed in Ca2+-free PSS (Fig. 1B) with attenuation of the
prolonged component of [Ca2+]i. Peak amplitudes of
[Ca2+]i responses did not appreciably differ between con-
trol or the different treatments. Overall results are summa-
rized in Fig. 1E (N = 4/treatment) and show durations
(measured at half-maximal of peak value) of ATP
responses were similar between Ca2+-free PSS and treat-
ments with the two SOC inhibitors. Respective inhibi-
tions of response durations relative to control ATP
response were 44% (0 PSS), 49% (gadolinium) and 55%
(SKF96365).
Expression of purinergic P2YR in C6 glioma
RT-PCR experiments were undertaken to determine the
expression of P2YR in unstimulated and ATP-stimulated
C6 cells. The study examined only those P2YR known to
be G protein coupled to IP3-dependent intracellular stores
[21,22] and included P2Y1, P2Y2, P2Y4 and P2Y6 recep-
Table 1: Primer sequences and product sizes
P2Y1R sense 5'-TGGCGTGGTGTACCCTCTCAAGTC-3' 558 bp
P2Y1R antisense 5'-CGGGACAGTCTCCTTCTGAATGTA-3'
P2Y2R sense 5'-CTGCCAGGCACCCGTGCTCTACTT-3' 340 bp
P2Y2R antisense 5'-CTGAGGTCAAGTGATCGGAAGGAG-3'
P2Y4R sense 5'-GGCATTGTCAGACACCTTG-3' 530 bp
P2Y4R antisense 5'-AAGACAGTCAGCACCACAG-3'
P2Y6R sense 5'-CGCTTCCTCTTCTATGCCA-3' 478 bp
P2Y6R antisense 5'-AGGCTGTCTTGGTGATGTG-3'
MCP-1 sense 5'-CCTGTTGTTCACAGTTGCTGCC-3' 396 bp
MCP-1 antisense 5'-TCTACAGAAGTGCTTGAGGTGGTTG-3'
IL-8 sense 5'-GAAGAT AGATTGCACCGATG-3' 365 bp
IL-8 antisense 5'-CATAGCCTCTCACACATTTC-3'
GAPDH sense 5'-TCCCTCAAGATTGTCAGCAA-3' 309 bp
GAPDH antisense 5'-AGATCCACAACGGATACATT-3'BMC Cancer 2009, 9:442 http://www.biomedcentral.com/1471-2407/9/442
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ATP-induced changes in [Ca2+]i in C6 glioma Figure 1
ATP-induced changes in [Ca2+]i in C6 glioma. (A) Representative response for ATP (100 μM) showing rapid and slow 
components of decay. (B) Typical ATP response in Ca2+-free PSS. (C) ATP response following gadolinium (Gd3+) pretreatment 
(1 μM, for 3 min). (D) ATP response in the presence of SKF96365 (25 μM, pretreatment for 3 min). (E) Quantification of dura-
tions of ATP responses for the different treatments (measured at one-half of peak response; N = 4/treatment). Values are 
mean ± SEM. *p < 0.001 compared with control.
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tors. Typical expression of these subtype receptors are pre-
sented in Fig. 2 for control and ATP stimulation of C6
glioma for 4 h. Expression of mRNA for any of the subtype
P2YR were unchanged between control and cells exposed
to ATP treatment. The levels of band intensities occurred
in the following order: P2Y2R > P2Y1R > P2Y6R > P2Y4R.
Consistent results were obtained in three additional
experiments with the intensity of P2Y2R exceeding levels
for the other subtype P2YR for both control and ATP-stim-
ulated glioma. Exposure of cells to longer-term ATP solu-
tion (48 h) had no significant effect to alter expression of
any of the subtype P2YR (data not shown).
Expression of chemokines MCP-1 and IL-8 in ATP-
stimulated C6 cells
Chemokines, such as MCP-1 and IL-8, released from ATP-
stimulated glioma could act to mobilize immune cells
nearby tumor microenvironments. Representative RT-
PCR for these two chemokines is presented in Fig. 3A for
the different treatments (4 h exposure) applied to C6 gli-
oma cells. Application of ATP (100 μM) markedly
enhanced expression of MCP-1 and IL-8 relative to con-
trol. Treatments of SKF96365 (25 μM) or gadolinium (1
μM) with ATP attenuated chemokine expression com-
pared with ATP alone. Application of SKF96365 or gado-
linium alone showed mRNA for MCP-1 and IL-8 similar
to control. Quantification for the relative expression of
the two chemokines with the different treatments (N = 4/
treatment) of C6 glioma is presented in Fig. 3B. ATP stim-
ulation increased expression of MCP-1 by 4.4-fold and IL-
8 by 3.2-fold relative to control. Expression of MCP-1 was
significantly reduced with SKF96365 (by 78%) and gado-
linium (by 64%) treatment of ATP-stimulated C6 relative
to ATP application alone. The corresponding decreases for
IL-8 were 46% with SKF96365 and 40% with gadolinium
with both values representing significant effects of the
SOC antagonists.
Production of MCP-1 and IL-8 in ATP-stimulated C6 cells
We next examined if the enhancing effect of ATP and the
inhibitory effect of SOC inhibitors on chemokine expres-
sion were translated at the protein levels. Preliminary
ELISA studies showed that production of both MCP-1 and
IL-8 was detectable as early as 4 h but in the low range of
detection limits for up to 24 h after ATP stimulation. Sub-
sequent experiments used a 48 h exposure of C6 glioma to
ATP with gadolinium studied as an SOC inhibitor. Sus-
tained exposure of C6 cells to SKF96365 (25 μM) caused
cytotoxicity to cells thus precluding use of this compound
for longer-term treatment. The overall results (N = 4/treat-
ment) show MCP-1 production was increased by 131%
with ATP stimulation compared with control (Fig. 4A).
Inclusion of gadolinium with ATP significantly attenuated
MCP-1 (by 64%) relative to ATP alone. Levels of IL-8 were
also enhanced by ATP (by 92%) compared to control (Fig.
4B). Addition of gadolinium with ATP was effective in
reducing levels of IL-8 by 54% compared to ATP applied
alone.
Discussion
The results from this work demonstrate that ATP stimula-
tion of C6 glioma causes an increased cellular expression
and production of the chemokines, MCP-1 and IL-8.
These chemokines could serve as potent factors to mobi-
lize tumor cells and also recruit microglia to help promote
Expression of P2YR linked to calcium stores in rodent C6 gli- oma Figure 2
Expression of P2YR linked to calcium stores in 
rodent C6 glioma. The levels of receptor subtype P2Y1, 
P2Y2, P2Y4 and P2Y6 were examined in control and ATP-
stimulated C6 cells (100 μM; 4 h exposure). The number of 
PCR cycles was 35 for all receptor subtypes. GAPDH served 
as a reaction standard. Data are representatives from 4 inde-
pendent experiments.
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Expression of MCP-1 and IL-8 in C6 cells Figure 3
Expression of MCP-1 and IL-8 in C6 cells. (A) Representative levels for MCP-1 (upper row) and IL-8 (middle row) for the 
different treatments (4 h) applied to C6 glioma. Concentrations of ATP, SKF96365 and gadolinium (Gd3+) were the same as 
used in Ca2+ studies (Fig. 1). GAPDH served as a reaction standard (lower row). (B) Overall results (N = 4 experiments) show-
ing relative chemokine expression normalized with GAPDH. Values are mean ± SEM. *p < 0.05 compared with control, **p < 
0.05 compared with ATP-treated group. 
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Production of MCP-1 and IL-8 in C6 glioma Figure 4
Production of MCP-1 and IL-8 in C6 glioma. C6 cells were treated with ATP (100 μM) in the presence, or absence, of 
gadolinium (Gd3+, 1 μM) for 48 h. (A) Levels of MCP-1 production (ng/ml) and (B) levels of IL-8 production (pg/ml) for the dif-
ferent treatments. Data are presented as mean ± SEM from 4 independent experiments. * indicates significant difference from 
control (p < 0.001) and ** indicates significant difference from ATP-treated group (p < 0.05).
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tumor development. Both expression and release of
chemokines were inhibited by antagonists for SOC-medi-
ated influx of Ca2+ suggesting ATP induced the activation
of a SOC-dependent pathway. Our findings lead to the
novel suggestion that ATP binding to a metabotropic
P2YR, coupled to activation of SOC, as an underlying
mechanism for chemokine production in tumor cells. As
discussed below, these findings are distinct from previous
work reporting increased levels of these chemokines
mediated by activation of the ionotropic P2X7R with the
ligand, BzATP [16].
Calcium-sensitive spectrofluorometry showed ATP-
induced increases in [Ca2+]i consisted of two components
of response decay with the rapid and slow phases repre-
senting respective store release and plasmalemmal entry
of Ca2+. In the presence of inhibitors of SOC, SKF96365
or gadolinium, the secondary but not initial, component
of response was suppressed. Both SOC inhibitors were
highly effective in blocking Ca2+ entry since durations of
ATP responses with either compound were similar to
those measured using Ca2+ free solution. It should be
noted that no specific SOC antagonist has yet been iden-
tified with both SKF96365 and gadolinium capable of
modulating other Ca2+ entry pathways. The findings and
implication for two Ca2+ influx channels in glioma, SOC
(this work) and P2X7R [16], are considered in more detail
below.
RT-PCR was used to determine expression of metabo-
tropic purinergic receptors P2Y1R, P2Y2R, P2Y4R and
P2Y6R which are linked to IP3-mediated mobilization of
[Ca2+]i [21]. Unstimulated C6 glioma showed a promi-
nent band intensity for P2Y2R with a relatively lower basal
expression for the other P2YR. The expression for any of
the subtype P2YR was not altered with exposure of C6
cells to ATP (4 h treatment). Interestingly, longer-term
exposure (48 h) of C6 glioma to ATP had no appreciable
effect to alter mRNA expression for any of the P2YR (data
not shown). Although our results show prominent expres-
sion of P2Y2R in glioma, future studies on protein levels
and use of specific purinergic agonists and antagonists
will have utility in linking specific P2YR with Ca2+-
dependent responses. It is noteworthy that P2Y subtype
receptors exhibit differential activation with purines with
P2Y1R and P2Y6R more sensitive to ADP while P2Y2R and
P2Y4R are more sensitive to ATP [21].
ATP stimulation of C6 glioma (4 h exposure) enhanced
expression of the potent microglial-mobilizing chemok-
ines, MCP-1 and IL-8. Expression of both chemokines
were significantly reduced with SKF96365 or gadolinium
included with the ATP stimulation. ELISA assay demon-
strated that production of both chemokines was relatively
low for ATP stimulation of C6 cells for durations less than
24 h but was enhanced with longer-term (48 h) exposure.
In the latter case, levels of MCP-1 and IL-8 were signifi-
cantly diminished with gadolinium included in the ATP
treatment. It is noteworthy that the stimulatory effects of
ATP on MCP-1 and IL-8 production were markedly lower
compared to other agents releasing chemokines from
astrocytic cell types. These agents include the P2X7R ago-
nist, BzATP [25] and the pro-inflammatory cytokines
TNF-α, and IL-1β [26,27].
The increased chemokine expression and production was
not directly attributable to changes in receptor expression
since none of the P2YR showed changes in band intensity
with ATP treatment (Fig. 2). It is possible that the high
basal levels of subtype P2Y2R expression in control would
preclude RT-PCR analysis showing any increases in this
subtype receptor after exposure of C6 cells to ATP. Gado-
linium treatment was demonstrated to significantly
reduce levels of MCP-1 and IL-8 in ATP-stimulated C6
cells. However, the inclusion of gadolinium with ATP did
not diminish chemokine productions to control levels.
Although P2X7R could contribute, this possibility is
unlikely since ATP levels near 1 mM are generally required
for activation of this receptor [28,29]. Our results do not
exclude involvement of other P2XR since it is known that
subtype receptors from the P2X family mediate influx of
Ca2+ into stimulated cells [12].
Together with previous data [16], C6 glioma cells are
shown to express at least two different purinergic-depend-
ent Ca2+ entry pathways which modulate cellular releases
of the chemokines, MCP-1 and IL-8. Activation of SOC
subsequent to ATP binding to a P2YR or activation of
P2X7R [16] with BzATP (ATP was not studied as an ago-
nist) is coupled to C6 chemokine production. The overall
results suggest that in C6 glioma, two different calcium
influx pathways converge with the same functional end-
point of enhanced chemokine release. The effects of SOC
inhibitors on rapid Ca2+ responses and on longer-term cell
functional responses indicates the involvement of Ca2+-
dependent transcription factors in mediating tumor cell
production of chemokines. One possibility is that release
of chemokines such as MCP-1 and IL-8 from C6 are mod-
ulated by SOC activation with physiological ATP concen-
trations whereas the purinergic P2X7R pathway only
contributes under extremely elevated levels of ATP.
Our findings suggest that pharmacological antagonism of
SOC could serve as a rationale strategy to inhibit tumor
growth. The SOC-dependent secretion of MCP-1 and IL-8
from C6 glioma would increase tumor cell mobility and
also act as mobilization and proliferation signals to direct
resident microglia into expanding tumors. It has been
pointed out that recruitment of microglia could aid in
supporting an immunosuppressive tumor environment toBMC Cancer 2009, 9:442 http://www.biomedcentral.com/1471-2407/9/442
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counter effects of T-cell-mediated killing of tumor cells
[4]. However, recent findings also indicate that under cer-
tain conditions activated microglia/macrophages are
capable of killing glioma cells [30,31]. Thus, it seems
likely that microglia/macrophages could play both pro- or
anti-neoplastic roles depending on the signaling factors
present in the tumor microenvironment.
Conclusions
Our results suggest ATP-induced Ca2+ entry, mediated by
activation of SOC in C6 glioma, as a mechanism linked to
the cellular expression and release of chemokines.
Increased levels of MCP-1 and IL-8 are predicted to
enhance the mobility of tumor cells and promote recruit-
ment of microglia into developing tumors thereby sup-
porting tumor growth. Pharmacological inhibition of
SOC in astroglioma is suggested as a novel treatment strat-
egy to inhibit tumor progression.
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